Study Group. (2001). "Renoprotective effect of atacand or avapro angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 atacand or avapro 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN.

Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. atacand or avapro (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker atacand or avapro Clarke WR, Berl atacand or avapro Pohl atacand or avapro Lewis JB, Ritz E, Atkins RC, atacand or avapro R, Raz I; Collaborative atacand or avapro Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist atacand or avapro in patients atacand or avapro nephropathy due to type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria.

PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3.